• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes

    ICON and Regeneron Win Best Partnership in Clinical Research Award from PharmaTimes

  2. Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Report, H1 2017 - Review of 14 Companies and Drug Profiles - Research and Markets

    Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline Report, H1 2017 - Review of 14 Companies and Drug Profiles - Research and Markets

  3. Gout Therapeutics Market to Reach $8.3 Billion by 2025 - Key Vendors are Takeda Pharmaceutical, Novartis, Savient Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Merck, Teijin Pharma & Regeneron - ...

    Gout Therapeutics Market to Reach $8.3 Billion by 2025 - Key Vendors are Takeda Pharmaceutical, Novartis, Savient Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Merck, Teijin Pharma & Regeneron - Research and Markets

  4. Global Wet Age Related Macular Degeneration (AMD) Market Analysis & Outlook 2017-2021 - Research and Markets

    Global Wet Age Related Macular Degeneration (AMD) Market Analysis & Outlook 2017-2021 - Research and Markets

  5. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  6. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  7. Our 5 Nominees for Domestic-Stock Fund Manager of the Year

    Standing out in a good year for stocks.

  8. Aberdeen to Buy Artio Global Investors

    As part of Aberdeen's acquisition of Artio, some international fund managers to depart. Also, a management change on a T. Rowe Price health-care fund, Columbia hires Putnam's former asset-allocation head, and ClearBridge and Legg Mason Capital Management funds to merge.

123

©2017 Morningstar Advisor. All right reserved.